Zoetis Past Earnings Performance
Past criteria checks 5/6
Zoetis has been growing earnings at an average annual rate of 10.8%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 8.2% per year. Zoetis's return on equity is 46.9%, and it has net margins of 27.4%.
Key information
10.8%
Earnings growth rate
11.6%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 8.2% |
Return on equity | 46.9% |
Net Margin | 27.4% |
Next Earnings Update | 02 May 2024 |
Recent past performance updates
Recent updates
Despite Lawsuit Risks: Why Zoetis Remains A Compelling Investment
Apr 15Zoetis Inc.'s (NYSE:ZTS) Shareholders Might Be Looking For Exit
Apr 12Zoetis: My Favorite Healthcare Stock Right Now
Mar 21Estimating The Fair Value Of Zoetis Inc. (NYSE:ZTS)
Mar 03Zoetis: Buy This High-Quality Dividend Growth Beast On Weakness
Feb 27Animal Kingdom's Ally: Zoetis And Its Path To 10%+ Returns
Jan 10Some Confidence Is Lacking In Zoetis Inc.'s (NYSE:ZTS) P/E
Jan 01Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's
Dec 14Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?
Dec 06Here's Why We Think Zoetis (NYSE:ZTS) Might Deserve Your Attention Today
Nov 18Zoetis: High-Quality Compounder With A Reasonable Price After Earnings
Nov 09Zoetis: Significant CapEx Investments For Long-Term Growth, But A Hold Now
Oct 26Zoetis Is An Impressive Healthcare Compounder
Sep 26Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)
Sep 25Here's Why Zoetis (NYSE:ZTS) Can Manage Its Debt Responsibly
Sep 04Zoetis: Pawses Pain, Librela OA Treatment Targets Furry Friends In The U.S.
Aug 22Should You Be Adding Zoetis (NYSE:ZTS) To Your Watchlist Today?
Aug 12Zoetis: My Dog Approves Of This Dividend Compounder
Jul 19Zoetis: A Purrfect Addition To Your Portfolio
Jun 22Does This Valuation Of Zoetis Inc. (NYSE:ZTS) Imply Investors Are Overpaying?
Jun 10These 4 Measures Indicate That Zoetis (NYSE:ZTS) Is Using Debt Reasonably Well
Apr 16Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)
Mar 10Zoetis rises on 2023 revenue forecast above estimates, Q4 profit in-line with consensus
Feb 14Zoetis Is An Awesome Dividend Growth Stock
Jan 17It's A Great Time To Buy Zoetis Shares
Jan 10Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's
Jan 03Is Zoetis (NYSE:ZTS) Using Too Much Debt?
Dec 29Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's
Dec 14Zoetis raises quarterly dividend by 15.4% to $0.375/share
Dec 08Estimating The Fair Value Of Zoetis Inc. (NYSE:ZTS)
Nov 20Zoetis' Q3 Earnings: Supply Issues Putting A Dent On Growth
Nov 08Zoetis Q3 2022 Earnings Preview
Nov 02Does Zoetis (NYSE:ZTS) Deserve A Spot On Your Watchlist?
Nov 02Zoetis declares $0.325 dividend
Oct 13A Rising Dollar May Mean Lower Zoetis Shares
Oct 07Is Zoetis (NYSE:ZTS) Using Too Much Debt?
Sep 15Zoetis cleared to acquire Jurox in Australia subject to divestiture
Sep 15Zoetis acquires Scottish animal health digital tech business
Sep 05Are Investors Undervaluing Zoetis Inc. (NYSE:ZTS) By 21%?
Aug 19Zoetis: Strong Q2 Underlying Growth But Hit By Strong U.S. Dollar
Aug 12Zoetis Q2 2022 Earnings Preview
Aug 03Zoetis: Lovable Company With Vision
Jul 20Revenue & Expenses BreakdownBeta
How Zoetis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 8,544 | 2,344 | 2,151 | 614 |
30 Sep 23 | 8,371 | 2,280 | 2,100 | 588 |
30 Jun 23 | 8,222 | 2,213 | 2,076 | 570 |
31 Mar 23 | 8,094 | 2,071 | 2,049 | 559 |
31 Dec 22 | 8,080 | 2,114 | 2,009 | 539 |
30 Sep 22 | 8,007 | 2,067 | 2,088 | 529 |
30 Jun 22 | 7,995 | 2,090 | 2,091 | 527 |
31 Mar 22 | 7,891 | 2,073 | 2,057 | 512 |
31 Dec 21 | 7,776 | 2,037 | 2,001 | 508 |
30 Sep 21 | 7,616 | 1,982 | 1,926 | 503 |
30 Jun 21 | 7,412 | 1,909 | 1,841 | 483 |
31 Mar 21 | 7,012 | 1,774 | 1,734 | 474 |
31 Dec 20 | 6,675 | 1,638 | 1,713 | 463 |
30 Sep 20 | 6,542 | 1,663 | 1,665 | 462 |
30 Jun 20 | 6,340 | 1,617 | 1,637 | 462 |
31 Mar 20 | 6,339 | 1,611 | 1,655 | 462 |
31 Dec 19 | 6,260 | 1,500 | 1,636 | 457 |
30 Sep 19 | 6,150 | 1,461 | 1,553 | 450 |
30 Jun 19 | 6,046 | 1,375 | 1,529 | 446 |
31 Mar 19 | 5,914 | 1,388 | 1,482 | 437 |
31 Dec 18 | 5,825 | 1,428 | 1,482 | 432 |
30 Sep 18 | 5,721 | 1,164 | 1,424 | 417 |
30 Jun 18 | 5,588 | 1,115 | 1,386 | 405 |
31 Mar 18 | 5,442 | 978 | 1,362 | 389 |
31 Dec 17 | 5,307 | 864 | 1,325 | 382 |
01 Oct 17 | 5,124 | 937 | 1,320 | 380 |
02 Jul 17 | 5,018 | 878 | 1,325 | 374 |
02 Apr 17 | 4,957 | 855 | 1,323 | 376 |
31 Dec 16 | 4,888 | 821 | 1,316 | 376 |
02 Oct 16 | 4,885 | 689 | 1,362 | 375 |
03 Jul 16 | 4,858 | 639 | 1,374 | 376 |
03 Apr 16 | 4,825 | 378 | 1,383 | 372 |
31 Dec 15 | 4,765 | 339 | 1,402 | 362 |
27 Sep 15 | 4,811 | 443 | 1,464 | 378 |
28 Jun 15 | 4,807 | 420 | 1,483 | 380 |
29 Mar 15 | 4,790 | 593 | 1,506 | 388 |
31 Dec 14 | 4,785 | 583 | 1,512 | 396 |
28 Sep 14 | 4,719 | 562 | 1,461 | 391 |
29 Jun 14 | 4,612 | 527 | 1,455 | 390 |
30 Mar 14 | 4,568 | 519 | 1,429 | 389 |
31 Dec 13 | 4,561 | 504 | 1,428 | 392 |
29 Sep 13 | 4,483 | 389 | 1,460 | 394 |
30 Jun 13 | 4,399 | 420 | 1,432 | 396 |
Quality Earnings: ZTS has high quality earnings.
Growing Profit Margin: ZTS's current net profit margins (27.4%) are higher than last year (26.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ZTS's earnings have grown by 10.8% per year over the past 5 years.
Accelerating Growth: ZTS's earnings growth over the past year (10.9%) exceeds its 5-year average (10.8% per year).
Earnings vs Industry: ZTS earnings growth over the past year (10.9%) exceeded the Pharmaceuticals industry -13.2%.
Return on Equity
High ROE: Whilst ZTS's Return on Equity (46.88%) is outstanding, this metric is skewed due to their high level of debt.